Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds.

"Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided significant contributions to the strategic direction and clinical development of JX-594 for the treatment of liver cancer, and we look forward to bringing his expertise in-house," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "In addition, as we advance our earlier stage pipeline products, Dr. Burke's direct clinical research experience using immunotherapeutics to treat multiple solid tumors will be instrumental as we pursue continued development of JX-929, JX-1395 and our next generation products."

Dr. Burke brings approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy.  His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases.  In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgeto
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
(Date:12/19/2014)... 2014 Research and Markets ( ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research ... a detailed assessment on technological advancements and market ... 1. The Smart Fabrics market is ...
(Date:12/19/2014)... Reports from CDC show approximately ... one or more chronic health conditions - including cardiovascular ... some of these diseases, but may not eliminate the ... While implanted nerve stimulation devices today offer relief, they ... can induce side effects. , To eliminate the ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Technology Innovations in Smart Fabrics (Technical Insights) 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... 07/06 2008 08/07, ... millions ... 73 14, Other EU Countries 9.7 22 17 ... 3 10 2.0 4 45, ...
... into a research collaboration to improve insect control in corn and ... ... Park, NC (Vocus) January 15, 2009 -– DuPont and Athenix today ... control in corn and soybeans. Under the agreement, DuPont business ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) ... Cambridge, Massachusetts with Vertex Pharmaceuticals Incorporated, totaling over 292,000 ... as Vertex,s Corporate Headquarters at 130 Waverly Street) and ... December 31, 2015. In total, Vertex leases approximately 685,000 ...
Cached Biology Technology:Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded 2Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded 3DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 2DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 3BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015 2BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015 3
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... causing urinary tract infections (UTIs), the second-most-common infection in ... with current antibiotics, according to new research from Extending ... Disease Dynamics, Economics & Policy. ETC released the ... to track changes in antibiotic drug use and resistance. ...
... Nov. 13, 2012 Millions of laboratory tests and ... processes. Quantum Materials Corporation has now developed tetrapod ... gain knowledge of how body systems function and chronic ... health and longevity. Conventionally, fluorescent tags or ...
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
Cached Biology News:Second most common infection in the US proving harder to treat with current antibiotics 2Second most common infection in the US proving harder to treat with current antibiotics 3Second most common infection in the US proving harder to treat with current antibiotics 4High Brightness Tetrapod Quantum Dots Developed 2High Brightness Tetrapod Quantum Dots Developed 3Plan to turn farm waste into paper earns students $15,000 2
... Captiva 96-well Filter Plates are offered in ... 0.45 um depth filter plates are ideal ... analysis. Filtration is simple, versatile, and necessary ... The Captiva 10 um glass fiber and ...
... Labeling Kit with CyScribe GFX Purification ... and purification of Cy3- and Cy5-labeled ... complete cDNA labeling and purification.Flexible and ... performing labeling reactions with either Cy3- ...
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Canine Serum...
Biology Products: